IP Library Granted Patent US 9,713,628
Granted Patent B2
US 9,713,628 · App. 14/847,686 · Granted Jul 25, 2017

Transplantation of neural cells

Inventors: Scott C. Baraban (Novato, CA); John L. Rubenstein (San Francisco, CA); Arturo Alvarez-Buylla (Woodside, CA)
Assignee: The Regents of the University of California
A61K35/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,713,628
App. No.
14/847,686
Granted
Jul 25, 2017
Kind
B2
Abstract

Restoration or increase of inhibitory interneuron function in vivo is achieved by transplantation of MGE cells into the brain. Compositions containing MGE cells are provided as are uses to treat various diseases characterized by abnormal inhibitory interneuron function or in cases where increase inhibition may ameliorate neural circuits that are abnormally activated.

Claims (31)

1. A method of reducing seizure activity in a mammal with a seizure disorder, the method comprising:

transplanting medial ganglionic eminence (MGE) cells into the central nervous system of a mammal with a seizure disorder; and

allowing the transplanted cells to migrate and integrate into the central nervous system of said mammal to form functional inhibitory interneurons that are associated with a reduction of seizure activity in the mammal,

thereby reducing seizure activity in the mammal.

2. The method of claim 1 , wherein the MGE cells are transplanted into the brain of said mammal.

3. The method of claim 1 , wherein the mammal is selected from the group consisting of mouse, rat, human, livestock animal and domestic animal.

4. The method of claim 1 , wherein the MGE cells are transplanted into a region of the central nervous system selected from the group consisting of cerebral cortex, hippocampus, thalamus, and striatum.

5. The method of claim 4 , wherein the MGE cells are transplanted into a region of the central nervous system which is free of lesions.

6. The method of claim 1 , wherein said transplanting comprises injecting dissociated MGE cells into the central nervous system.

7. The method of claim 6 , wherein the MGE cells are injected in association with a carrier.

8. The method of claim 1 , wherein the mammal is a human.

9. The method of claim 1 , wherein the mammal is an adult.

10. The method of claim 1 , wherein the mammal is a juvenile.

11. The method of claim 1 , wherein said seizure disorder is epilepsy.

12. A method of increasing the seizure latency in a mammal with a reduced capacity to synthesize γ-aminobutyric acid (GABA) in the central nervous system (CNS), the method comprising:

transplanting medial ganglionic eminence (MGE) cells into the central nervous system of a mammal with a reduced capacity to synthesize GABA in the CNS; and

allowing the transplanted cells to migrate and integrate into the CNS of said mammal to form functional inhibitory interneurons that are associated with an increase in GABA production in the CNS of the mammal,

thereby increasing seizure latency in the mammal.

13. The method of claim 12 , wherein said transplanting comprises injecting dissociated MGE cells into the central nervous system.

14. The method of claim 13 , wherein the MGE cells are injected in association with a carrier.

15. The method of claim 12 , wherein the mammal is a human.

16. The method of claim 12 , wherein the mammal is an adult.

17. The method of claim 12 , wherein said mammal suffers from epilepsy.

18. A method of treating a mammal with demonstrated increased neural hyperexcitability in the central nervous system (CNS), the method comprising:

transplanting medial ganglionic eminence (MGE) cells into the central nervous system of a mammal with demonstrated increased neural hyperexcitability; and

allowing the transplanted cells to migrate and integrate into the CNS of said mammal to form functional inhibitory interneurons that are associated with reduced neural hyperexcitability and improved function in the CNS of the mammal,

thereby treating the mammal.

19. The method of claim 18 , wherein said transplanting comprises injecting dissociated MGE cells into the central nervous system.

20. The method of claim 19 , wherein the MGE cells are injected in association with a carrier.

21. The method of claim 18 , wherein the mammal is a human.

22. The method of claim 18 , wherein the mammal is an adult.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2015
From: BARABAN, SCOTT C.; RUBENSTEIN, JOHN L.; ALVAREZ-BUYLLA, ARTURO
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 036962/0319 →
Continuity (3)
Continuation 12161527
Provisional Application 60760676 · Jan 20, 2006
Related Publication 20160008403A1 · Jan 14, 2016